Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: J Immunol. 2019 May 20;203(1):105–116. doi: 10.4049/jimmunol.1801032

Figure 4.

Figure 4

A) OC formed in cultures of male BMMs treated with M-CSF + RANKL (30 ng/ml for both) and 0, 10 or 30 ng/ml of TNF. Cells were from WT or PAR1 KO male mice that were cultured for 4 days. N = 3 – 4 for each group. * Significantly different from WT, p < 0.05.

B) OC formed in cultures of male BMMs treated with M-CSF (30 ng/ml) + TNF (10 ng/ml) and 0, 10 or 30 ng/ml of RANKL. Cells were from WT or PAR1 KO male mice that were cultured for 4 days. N = 3 – 4 for each group. * Significantly different from WT, p < 0.05.